Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

GLP-1 drugs are blockbuster medications for weight loss and Type 2 diabetes. Now doctors are trying them for lymphedema, ...

By Puyaan Singh (Reuters) - The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Also Read: Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug Novo Holdings CEO Kasim Kutay called 2024 “a very strong year” since the portfolio generated returns of 18%. That’s ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...